Imaging Coronary Microvascular Dysfunction (CMD) Study

Launched by ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · Nov 21, 2022

Keywords

ClinConnect Summary

The Imaging Coronary Microvascular Dysfunction (CMD) Study is researching a condition called angina, which is chest pain or discomfort that many people experience due to heart issues. Surprisingly, many patients with angina do not have blocked arteries, a situation known as non-obstructive coronary artery disease (CAD). This study aims to develop a simple, non-invasive way to diagnose and manage patients who have this condition, focusing on improving their symptoms and overall quality of life through advanced imaging techniques. The research will take place at Mount Sinai Morningside and will involve about 70 participants over two years.

To be eligible for this study, participants should be experiencing symptoms of angina or shortness of breath, and they should have been diagnosed with non-obstructive CAD through specific heart imaging tests. Certain health conditions, like severe heart problems or kidney issues, may exclude a person from participating. If you join the study, you can expect to undergo non-invasive imaging tests and receive personalized care based on the results to help manage your symptoms better. This trial is a valuable opportunity for patients who are looking for more effective ways to address their heart-related symptoms without invasive procedures.

Gender

ALL

Eligibility criteria

• Inclusion criteria:
• • Patients with symptoms of exertional angina and/or dyspnea (confirmed on Seattle Angina Questionnaire and Rose Dyspnea Questionnaire)
• • Evidence of non-obstructive CAD on CCTA or coronary angiography (no stenosis \>50% and/or FFR if performed \>0.80)
• Exclusion criteria:
• • Patients with reduced LVEF (\<50%) or diagnosis of cardiomyopathy
• • Patients with co-existent moderate or severe valve disease
• • Patients with eGFR \<30 ml/min/m2
• • History of prior coronary revascularization
• • Non-coronary indication for CCTA or coronary angiogram determining eligibility
• • Contraindications to regadenoson (severe asthma/chronic obstructive pulmonary disease, brady-arrhythmias, or systolic blood pressure \<90 mm Hg)
• • Inability to provide informed consent
• • Pregnancy